AOP Orphan Pharmaceuticals
As of the edition of 20 October 2026, AOP Orphan Pharmaceuticals runs 4 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ropeginterferon alfa-2b | Ends 2033 (computed from the first US licence) | 0 |
| Landiolol | Ends 2029 (exclusivity) | 1 |
A route B row is one company at one target.
Where its trials are
- Blood and lymph: 4 trials led
- Cancer: 4 trials led
- Digestive system: 1 trials led